Covered recipient · General Payments record
ASHLEY BROYLES
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$2,576.41
- Reported across 182 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $528.92 | 35 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $190.08 | 15 |
| Novo Nordisk AS | $98.66 | 6 |
| PFIZER INC. | $65.90 | 4 |
| Lilly USA, LLC | $52.27 | 3 |
| Actelion Pharmaceuticals US, Inc. | $33.77 | 2 |
| Amgen Inc. | $33.70 | 2 |
| Philips Electronics North America Corporation | $21.81 | 1 |
| Antares Pharma, Inc. | $17.63 | 1 |
| Edwards Lifesciences Corporation | $15.10 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (35)
Sorted by paying entity, then date · as published by CMS
Program year 2024 202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $20.94 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106838363 | CMS |
| ABBVIE INC. | $20.98 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106838365 | CMS |
| ABBVIE INC. | $12.07 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106838367 | CMS |
| ABBVIE INC. | $14.55 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106838369 | CMS |
| ABBVIE INC. | $18.54 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106838371 | CMS |
| ABBVIE INC. | $11.38 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106838373 | CMS |
| ABBVIE INC. | $19.47 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106838375 | CMS |
| ABBVIE INC. | $3.19 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106838377 | CMS |
| ABBVIE INC. | $9.83 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106838379 | CMS |
| ABBVIE INC. | $12.11 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106838381 | CMS |
| ABBVIE INC. | $2.39 | 08/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106838383 | CMS |
| ABBVIE INC. | $15.64 | 08/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106838385 | CMS |
| ABBVIE INC. | $12.63 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106838387 | CMS |
| ABBVIE INC. | $4.22 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106838389 | CMS |
| ABBVIE INC. | $12.14 | 11/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106838391 | CMS |
| Actelion Pharmaceuticals US, Inc. | $14.98 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078922361 | CMS |
| Actelion Pharmaceuticals US, Inc. | $18.79 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078922547 | CMS |
| Amgen Inc. | $19.81 | 03/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115465880 | CMS |
| Amgen Inc. | $13.89 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117515583 | CMS |
| Antares Pharma, Inc. | $17.63 | 12/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146497818 | CMS |
| Edwards Lifesciences Corporation | $15.10 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138772309 | CMS |
| Lilly USA, LLC | $18.04 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135539848 | CMS |
| Lilly USA, LLC | $17.48 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135565376 | CMS |
| Lilly USA, LLC | $16.75 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135539844 | CMS |
| Novo Nordisk Inc | $13.88 | 01/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100526657 | CMS |
| Novo Nordisk Inc | $14.18 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100362059 | CMS |
| Novo Nordisk Inc | $14.30 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100466674 | CMS |
| Novo Nordisk Inc | $17.21 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100278638 | CMS |
| Novo Nordisk Inc | $21.28 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100449461 | CMS |
| Novo Nordisk Inc | $17.81 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100312183 | CMS |
| PFIZER INC. | $17.15 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131349921 | CMS |
| PFIZER INC. | $16.88 | 07/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131757550 | CMS |
| PFIZER INC. | $16.93 | 10/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132081436 | CMS |
| PFIZER INC. | $14.94 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131112692 | CMS |
| Philips North America LLC | $21.81 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146855193 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.